医学
卡铂
彭布罗利珠单抗
肿瘤科
紫杉醇
头颈部
内科学
基底细胞
头颈部鳞状细胞癌
临床研究阶段
头颈部癌
化疗
放射治疗
外科
癌症
免疫疗法
顺铂
作者
Marcin Dzienis,Juan Cundom,C.S. Fuentes,Anna Spreafico,Melanie Nordlinger,Andrea Viviana Pastor,Erin R. Alesi,A. Neki,Andrea S. Fung,Iane Pinto Figueiredo Lima,Peter Oppelt,Geraldo Felício Cunha-Junior,Barbara Burtness,Fábio Franke,Jennifer Tseng,A.J. Joshi,Joy McCarthy,Ramona F. Swaby,Yulia Sidi,Burak Gümüşçü,Niroshini Naicker,Gilberto de Castro
摘要
Standard-of-care first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is pembrolizumab plus platinum and fluorouracil (FU). However, FU is associated with potential challenges (continuous 4-day infusion, high administration costs, and cardiovascular and gastrointestinal toxicities), creating a clinical need for alternative chemotherapy combinations. We evaluated the efficacy and safety of first-line pembrolizumab plus carboplatin and paclitaxel for R/M HNSCC in the open-label, single-arm, phase IV KEYNOTE-B10 study (ClinicalTrials.gov identifier: NCT04489888).
科研通智能强力驱动
Strongly Powered by AbleSci AI